A nurse is reviewing the laboratory values of a client with bone marrow suppression and is receiving Oprelvekin. Which of the following values would indicate an improvement in the client's condition?

Coronary artery bypass graft (CABG) surgery is performed to restore adequate myocardial blood flow in clients with significant coronary artery disease. Preoperative assessment focuses on identifying unstable cardiac conditions that may increase perioperative risk. Signs of acute myocardial ischemia require immediate intervention because they indicate ongoing cardiac tissue hypoxia. Stabilizing the client before surgery is essential to reduce the risk of intraoperative complications and myocardial damage.

Rationale:
A. The client is scheduled to receive preoperative antibiotics is a routine perioperative measure and does not indicate an urgent problem. Antibiotics are commonly administered before CABG surgery to reduce the risk of postoperative infection, particularly mediastinitis. This is standard care and not a condition requiring immediate intervention.

B. The client has a history of hypertension is a common comorbidity in clients undergoing CABG surgery and is expected. While blood pressure must be controlled preoperatively, a history of hypertension alone does not represent an acute or urgent finding. Management typically involves continued medication and monitoring rather than emergency intervention.

C. The client reports severe chest pain and diaphoresis is the most urgent finding because it suggests ongoing myocardial ischemia or possible acute coronary syndrome. These symptoms indicate inadequate oxygen supply to the heart muscle and require immediate evaluation and stabilization before surgery. Proceeding with CABG without addressing active ischemia increases the risk of perioperative myocardial infarction.

D. The client expresses anxiety about the surgery is a common and expected psychological response. Preoperative anxiety can be addressed through education, reassurance, and emotional support. While important for holistic care, it does not represent an immediate physiological threat requiring urgent intervention compared to active cardiac ischemia.

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system characterized by periods of relapse and remission. Disease-modifying therapies are used to reduce inflammatory activity, decrease relapse frequency, and slow long-term neurological deterioration. Interferon beta is one of the first-line treatments for relapsing forms of MS. It works by modulating the immune response to reduce autoimmune attack on myelin.

Rationale:
A. Interferon beta medications are indicated for acute relapses of multiple sclerosis is incorrect because these drugs are not used to treat acute exacerbations. Acute relapses are typically managed with high-dose corticosteroids to rapidly reduce inflammation. Interferon beta is a long-term disease-modifying therapy rather than an acute treatment.

B. Interferon beta medication may help to reduce the frequency of relapses and slow disease progression in multiple sclerosis is correct. It modulates immune system activity, reducing inflammatory attacks on myelin and decreasing the number and severity of relapses. Over time, this can also slow the accumulation of neurological disability associated with MS progression.

C. Interferon beta medications are contraindicated for clients who have multiple sclerosis is incorrect because these drugs are specifically approved for use in relapsing forms of MS. They are commonly prescribed as part of first-line disease-modifying therapy to manage the long-term course of the disease.

D. Interferon beta medications are only effective in managing symptoms but do not alter the disease course of multiple sclerosis is incorrect because these medications are disease-modifying rather than purely symptomatic. They reduce disease activity by decreasing immune-mediated damage to myelin, thereby influencing the progression of MS rather than only relieving symptoms.